Other Events ·
Conexeu Sciences completes P.R.O.O.F. phase of CXU platform preclinical program, targeting Q1 2027 510(k) submission
CNXUConexeu Sciences Inc.
Conexeu Sciences Inc. announced the completion of the P.R.O.O.F. phase of its CXU™ platform preclinical program, demonstrating successful tissue restoration in both small-volume facial and large-volume subcutaneous models. The 12-month study met performance benchmarks for injectability and volumizing performance, supporting the company's planned 510(k) regulatory submission for wound care in Q1 2027. Conexeu Sciences Inc. is a biotechnology company developing a flowable collagen platform for medical aesthetics and wound care applications.